Amuity Ellipta Approved for the Treatment of Asthma
August 25, 2014 – Amuity Ellipta (fluticasone furoate inhalation powder) was approved by the Food and Drug Administration (FDA). Amuity Ellipta is manufactured by GlaxoSmithKline.
Amuity Ellipta is a once a day inhaled corticosteroid administered as prophylactic therapy for the maintenance treatment of asthma. Dosing starts at 100mcg or 200 mcg and depends on the severity of the asthma and prior treatment outcomes. Amuity Ellipta is anticipated to be available on the market early in 2015.
Adverse reactions or quality problems experienced with the use of a recalled product may be reported to the FDA’s MedWatch Adverse Event Reporting Program either online, by regular mail or by fax.
- Complete and submit the report Online: www.fda.gov/medwatch/report.htm
- Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178
Actual drug patent expiration dates and a availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.
*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.